Armod: Advanced Wakefulness for Enhanced Cognitive Performance
| Product dosage: 150 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.31 | $69.28 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $138.55 $85.34 (38%) | 🛒 Add to cart |
| 90 | $1.10 | $207.83 $99.40 (52%) | 🛒 Add to cart |
| 180 | $1.03 | $415.66 $185.74 (55%) | 🛒 Add to cart |
| 270 | $0.95
Best per pill | $623.49 $256.02 (59%) | 🛒 Add to cart |
Synonyms | |||
Armod is a prescription medication containing Armodafinil, the R-enantiomer of modafinil, designed to promote wakefulness in individuals with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. As a central nervous system stimulant, it functions by altering the natural chemicals (neurotransmitters) in the brain that regulate the sleep-wake cycle. Unlike traditional stimulants, Armodafinil offers a more refined pharmacological profile with a longer half-life, providing sustained alertness without the pronounced peaks and troughs associated with other agents. Its mechanism targets hypothalamic regions, promoting histamine release and inhibiting dopamine reuptake, which contributes to its efficacy in maintaining daytime wakefulness. Clinicians favor Armod for its targeted action and favorable side effect profile, making it a cornerstone in the management of sleep-wake disorders.
Features
- Contains 150mg or 250mg of Armodafinil per tablet
- Extended duration of action (approximately 12–15 hours)
- Non-amphetamine stimulant with low abuse potential
- Schedule IV controlled substance
- White to off-white, round tablets with functional score
- Manufactured under cGMP standards
Benefits
- Promotes sustained wakefulness and reduces unintended sleep episodes
- Enhances cognitive function, including attention and executive processing
- Improves quality of life by enabling normal daily and occupational activities
- Minimizes the residual sedative effects often seen with traditional stimulants
- Supports adherence through once-daily dosing convenience
- Exhibits a lower incidence of jitteriness or rebound hypersomnia compared to older agents
Common use
Armod is indicated for the improvement of wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) (as adjunct to primary treatments like CPAP), and shift work sleep disorder (SWSD). In narcolepsy, it mitigates cataplexy-associated sleep attacks; in OSA, it addresses residual daytime sleepiness despite adequate airway management; and in SWSD, it helps maintain alertness during work hours for those with non-traditional schedules. Off-label uses may include adjunctive management in attention deficit hyperactivity disorder (ADHD) and fatigue associated with medical conditions like multiple sclerosis or depression, though these are not FDA-approved indications.
Dosage and direction
The recommended dose for Armod is 150mg or 250mg taken orally once daily, in the morning for narcolepsy or OSA, or approximately one hour prior to the start of a work shift for SWSD. Tablets should be swallowed whole with water, with or without food—though high-fat meals may delay absorption. Dosage adjustment is not typically required for elderly patients but should be considered in those with severe hepatic impairment, with a recommended dose of 50mg. Treatment should be initiated at the lowest effective dose and titrated based on therapeutic response and tolerability. Do not crush, chew, or split tablets.
Precautions
Patients should be cautioned about the potential for Armod to reduce the efficacy of hormonal contraceptives; alternative or additional non-hormonal methods of contraception are advised during and for one month after discontinuation. Use with caution in those with a history of psychosis, depression, mania, or cardiovascular disease due to potential exacerbation. Regular monitoring of blood pressure and heart rate is recommended. Armod may impair the ability to engage in potentially hazardous activities, such as operating machinery or driving, until the individual’s response is known. Abrupt discontinuation after prolonged use should be avoided to prevent withdrawal effects.
Contraindications
Armod is contraindicated in patients with known hypersensitivity to Armodafinil, modafinil, or any component of the formulation. It should not be used in those with a history of symptomatic cardiovascular disease, including left ventricular hypertrophy, mitral valve prolapse, or arrhythmias. Use is also contraindicated in patients with a history of drug abuse or addiction. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of hypertensive crisis; a 14-day washout period is required before initiating Armod.
Possible side effect
Common side effects (≥5%) include headache, nausea, dizziness, insomnia, anxiety, and dry mouth. Less frequently, rash, palpitations, diarrhea, or nervousness may occur. Serious but rare adverse effects include Stevens-Johnson syndrome, angioedema, multiorgan hypersensitivity reactions, and psychiatric symptoms such as aggression, hallucinations, or suicidal ideation. Any signs of serious rash or allergic reaction warrant immediate discontinuation and medical attention. Most side effects are dose-dependent and may diminish with continued use or dose adjustment.
Drug interaction
Armod is a moderate inducer of CYP3A4/5 and may reduce the plasma concentrations of substrates of this enzyme, such as cyclosporine, ethinyl estradiol, midazolam, and triazolam. Conversely, strong CYP3A4 inducers (e.g., carbamazepine, rifampin) may decrease Armodafinil levels. Co-administration with drugs that inhibit CYP2C19 (e.g., fluoxetine, omeprazole) may increase Armodafinil exposure. Use with warfarin may necessitate more frequent INR monitoring due to potential interaction. Concomitant use with other CNS stimulants may exacerbate sympathetic effects.
Missed dose
If a dose is missed, it should be taken as soon as possible on the same day. However, if it is nearing the evening or bedtime, the missed dose should be skipped to prevent insomnia. Doubling the dose is not recommended. Patients should maintain a consistent dosing schedule to ensure optimal therapeutic effect.
Overdose
Symptoms of overdose may include insomnia, central nervous system excitation such as restlessness, disorientation, confusion, agitation, tachycardia, hypertension, and gastrointestinal distress. In severe cases, hallucinations or seizures may occur. There is no specific antidote; management involves symptomatic and supportive care, including cardiovascular monitoring and activated charcoal if ingestion was recent. Hemodialysis is not expected to be effective due to high protein binding.
Storage
Store at room temperature (20–25°C or 68–77°F), in a tightly closed container, away from light, moisture, and heat. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Dispose of unused medication via a drug take-back program or according to local regulations to prevent misuse.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual responses to Armod may vary, and only a licensed practitioner can determine its appropriateness based on a patient’s specific health profile.
Reviews
Clinical studies and patient reports consistently highlight Armod’s efficacy in promoting wakefulness and improving functional outcomes. In a 12-week randomized controlled trial, 74% of patients with narcolepsy reported significant reduction in daytime sleepiness compared to placebo. Users frequently note improved ability to concentrate and complete tasks without the “crash” associated with other stimulants. However, some report initial side effects like headache, which often subside with continued use. Overall, it is regarded as a valuable tool in sleep medicine when used under appropriate supervision.